Literature DB >> 33129895

Bi-allelic pathogenic variations in DNAJB11 cause Ivemark II syndrome, a renal-hepatic-pancreatic dysplasia.

Penelope Jordan1, Christelle Arrondel2, Bettina Bessières3, Aude Tessier3, Tania Attié-Bitach4, Sarah Guterman5, Vincent Morinière1, Corinne Antignac6, Sophie Saunier2, Marie-Claire Gubler2, Laurence Heidet7.   

Abstract

DNAJB11 (DnaJ Heat Shock Protein Family (Hsp40) Member B11) heterozygous loss of function variations have been reported in autosomal dominant cystic kidney disease with extensive fibrosis, associated with maturation and trafficking defect involving both the autosomal dominant polycystic kidney disease protein polycystin-1 and the autosomal dominant tubulointerstitial kidney disease protein uromodulin. Here we show that biallelic pathogenic variations in DNAJB11 lead to a severe fetal disease including enlarged cystic kidneys, dilation and proliferation of pancreatic duct cells, and liver ductal plate malformation, an association known as Ivemark II syndrome. Cysts of the kidney were developed exclusively from uromodulin negative tubular segments. In addition, tubular cells from the affected kidneys had elongated primary cilia, a finding previously reported in ciliopathies. Thus, our data show that the recessive disease associated with DNAJB11 variations is a ciliopathy rather than a disease of the autosomal dominant tubulointerstitial kidney disease spectrum, and prompt screening of DNAJB11 in fetal hyperechogenic/cystic kidneys.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNAJB11; genetics; prenatal cystic kidney disease; primary cilia

Mesh:

Substances:

Year:  2020        PMID: 33129895     DOI: 10.1016/j.kint.2020.09.029

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

Authors:  Sarah R Senum; Ying Sabrina M Li; Katherine A Benson; Giancarlo Joli; Eric Olinger; Sravanthi Lavu; Charles D Madsen; Adriana V Gregory; Ruxandra Neatu; Timothy L Kline; Marie-Pierre Audrézet; Patricia Outeda; Cherie B Nau; Esther Meijer; Hamad Ali; Theodore I Steinman; Michal Mrug; Paul J Phelan; Terry J Watnick; Dorien J M Peters; Albert C M Ong; Peter J Conlon; Ronald D Perrone; Emilie Cornec-Le Gall; Marie C Hogan; Vicente E Torres; John A Sayer; Peter C Harris
Journal:  Am J Hum Genet       Date:  2021-12-09       Impact factor: 11.043

2.  More dissimilarities than affinities between DNAJB11-PKD and ADPKD.

Authors:  Isabella Pisani; Marco Allinovi; Viviana Palazzo; Paola Zanelli; Micaela Gentile; Maria Teresa Farina; Sara Giuliotti; Paolo Cravedi; Marco Delsante; Umberto Maggiore; Enrico Fiaccadori; Lucio Manenti
Journal:  Clin Kidney J       Date:  2022-01-31

3.  Biallelic Mutations in DNAJB11 are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family.

Authors:  Esra Arslan Ateş; Ayberk Turkyilmaz; Kenan Delil; Ceren Alavanda; Mehmet Ali Söylemez; Bilgen Bilge Geçkinli; Pinar Ata; Ahmet Arman
Journal:  Mol Syndromol       Date:  2021-04-01

4.  Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway.

Authors:  Xiaoli Yin; Xiaodong Tan; Peng Liu; Fuqiang Zu; Hui Chen
Journal:  Cell Mol Biol Lett       Date:  2022-10-08       Impact factor: 8.702

Review 5.  Renal-hepatic-pancreatic dysplasia-1 with a novel NPHP3 genotype: a case report and review of the literature.

Authors:  Hui Zhu; Zhi-Hui Zhao; Shu-Yao Zhu; Fu Xiong; Li-Hong He; Yong Zhang; Jin Wang
Journal:  BMC Pediatr       Date:  2022-10-18       Impact factor: 2.567

6.  Expanding the genetic landscape of oral-facial-digital syndrome with two novel genes.

Authors:  Alanna Strong; Laurie Simone; Anthony Krentz; Courtney Vaccaro; Deborah Watson; Hayley Ron; Jennifer M Kalish; Helio F Pedro; Elaine H Zackai; Hakon Hakonarson
Journal:  Am J Med Genet A       Date:  2021-06-15       Impact factor: 2.802

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.